While the specific drugs tested were developed for cancer treatment and have not been tested for chronic treatment of NAFLD, our data suggest that compatible pharmaceuticals that target the same regulatory pathways could be successful in reducing hepatic lipid accumulation in patients with PNPLA3 variants. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.